LIVIVO - Search results -

Search results

Result 1 - 10 of total 90

Search options

Article ; Online: Rolle, Arbeitsweise und Empfehlungen der Ständigen Impfkommission (STIKO) im Kontext der COVID-19-Pandemie.

Vygen-Bonnet, Sabine / Schlaberg, Johanna / Koch, Judith

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

2022 Volume 65, Issue 12, Page(s) 1251–1261

Abstract: The Standing Committee on Vaccination (STIKO) is a voluntary body whose 18 experts are appointed by the Federal Ministry of Health. The scientific work of STIKO is supported by a scientific secretariat at the Robert Koch Institute. The STIKO develops ... ...

Title translation	Role, working methods and recommendations of the Standing Committee on Vaccinations (STIKO) in the context of the COVID-19 pandemic.
Abstract	The Standing Committee on Vaccination (STIKO) is a voluntary body whose 18 experts are appointed by the Federal Ministry of Health. The scientific work of STIKO is supported by a scientific secretariat at the Robert Koch Institute. The STIKO develops independent vaccination recommendations for Germany using the methodology of evidence-based medicine (EBM).During the COVID-19 pandemic, STIKO faced major challenges. Several COVID-19 vaccines based on new technologies were approved within a very short time. The benefit-risk assessment had to be carried out according to the current state of knowledge. The vaccination recommendations had to be continuously adapted to the constantly changing epidemiology of SARS-CoV‑2, increasing vaccine availability, new approvals, extensions of indications, and safety signals of vaccines. STIKO has adapted its way of working to the situation; the experts showed an impressive commitment during the pandemic. Even under time pressure, STIKO adhered to the principles of EBM and developed evidence-based vaccination recommendations. Before the final decision was made, STIKO submitted every vaccination recommendation to a commenting procedure with the stakeholders (e.g., medical societies and health authorities). Despite the short deadlines, the stakeholders made extensive and constructive comments and gave STIKO the opportunity to discuss and adapt their recommendations, consider the feedback, and thus build on a broad consensus.The past few months have shown that it is possible and rational to developing vaccination recommendations based on the principles of EBM even during a pandemic. Sufficient human resources in the STIKO office are essential.
Language	German
Publishing date	2022-11-22
Publishing country	Germany
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	1461973-8
ISSN	1437-1588 ; 1436-9990
ISSN (online)	1437-1588
ISSN	1436-9990
DOI	10.1007/s00103-022-03610-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Un I Zs.525: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Changes in malaria epidemiology in Germany, 2001-2016: a time series analysis.

Vygen-Bonnet, Sabine / Stark, Klaus

Malaria journal

2018 Volume 17, Issue 1, Page(s) 28

Abstract: Background: German surveillance data showed a sharp rise of malaria cases in 2014 and 2015 due to the increased arrival of refugees from malaria endemic countries. A time series analysis of data from 2001 to 2016 was performed in order to describe the ... ...

Abstract	Background: German surveillance data showed a sharp rise of malaria cases in 2014 and 2015 due to the increased arrival of refugees from malaria endemic countries. A time series analysis of data from 2001 to 2016 was performed in order to describe the epidemiology of imported malaria in Germany in general and of the recent increase in particular. Results: In total, 11,678 malaria cases were notified between 2001 and 2016 (range 526-1063 cases/year). Newly arriving refugees averaged 10 cases/year (1.5%) in 2001-13 and 292.5 cases/year (28.3%) in 2014-15. Plasmodium (P.) falciparum was the most frequently reported species (range 57.2-85.8%), followed by P. vivax (range during 2001-2013: 7.6-18.1%; during 2014-2015, mean 31.3%). In 2014-15, 22.3% of all P. vivax cases were refugees from Eritrea and 3.3% from other countries of the Horn of Africa; in 2015 and 2016, 19.5% were refugees from Afghanistan and Pakistan. Five P. knowlesi malaria infections were reportedly acquired in Thailand between 2012 and 2016. Total numbers of malaria notifications among native Germans and residents with migration background showed an increasing trend since 2007. Chemoprophylaxis use was reported for 24.3% (1695/6984) of cases and showed a declining trend. Native German cases took significantly more frequently chemoprophylaxis than cases with migration background (32.6% vs. 17.9%; p < 0.001). Discussion/conclusions: The steep rise in vivax malaria notifications in 2014 and 2015 was mainly due to newly arriving refugees from Eritrea but also from other countries of the Horn of Africa and South Asia. Clinicians should include malaria in their differential diagnosis in case of a febrile illness in the respective population and consider vivax malaria even if arrival to Germany dates back several months. Over the past 10 years, malaria notifications among native Germans and residents with migration background showed an increasing trend. Use of chemoprophylaxis was insufficient in both groups and deteriorating. New strategies need to be found to increase compliance to chemoprophylaxis recommendations. The surveillance provides valuable data for epidemiological assessment of imported malaria in Germany.
MeSH term(s)	Adolescent ; Adult ; Antimalarials/therapeutic use ; Chemoprevention/statistics & numerical data ; Child ; Child, Preschool ; Communicable Diseases, Imported/epidemiology ; Communicable Diseases, Imported/parasitology ; Female ; Germany/epidemiology ; Humans ; Malaria/epidemiology ; Malaria/parasitology ; Male ; Plasmodium/isolation & purification ; Plasmodium/physiology ; Refugees/statistics & numerical data ; Travel/statistics & numerical data ; Young Adult
Chemical Substances	Antimalarials
Language	English
Publishing date	2018-01-15
Publishing country	England
Document type	Journal Article
ISSN	1475-2875
ISSN (online)	1475-2875
DOI	10.1186/s12936-018-2175-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Needs and feasibility of living systematic reviews (LSRs): Experience from LSRs on COVID-19 vaccine effectiveness.

Külper-Schiek, Wiebe / Thielemann, Iris / Pilic, Antonia / Meerpohl, Joerg J / Siemens, Waldemar / Vygen-Bonnet, Sabine / Koch, Judith / Harder, Thomas / Piechotta, Vanessa

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

2024

Abstract: During 2021 and 2023, a team of researchers at the Robert Koch Institute (RKI) and partnering institutions conducted two living systematic reviews (LSRs) on the effectiveness of COVID-19 vaccines in different age groups to inform recommendations of the ... ...

Abstract	During 2021 and 2023, a team of researchers at the Robert Koch Institute (RKI) and partnering institutions conducted two living systematic reviews (LSRs) on the effectiveness of COVID-19 vaccines in different age groups to inform recommendations of the Standing Committee on Vaccination in Germany (Ständige Impfkommission, STIKO). Based on our experience from the realization of these LSRs, we developed certain criteria to assess the needs and feasibility of conducting LSRs. Combining these with previously established criteria, we developed the following set to inform future planning of LSRs for STIKO: Needs criterion (N)1: Relevance of the research question, N2: Certainty of evidence (CoE) at baseline; N3: Expected need for Population-Intervention-Comparator-Outcome (PICO) adaptations; N4: Expected new evidence over time; N5: Expected impact of new evidence on CoE; Feasibility criterion (F)1: Availability of sufficient human resources; F2: Feasibility of timely dissemination of the results to inform decision-making. For each criterion we suggest rating options which may support the decision to conduct an LSR or other forms of evidence synthesis when following the provided flowchart. The suggested criteria were developed on the basis of the experiences from exemplary reviews in a specific research field (i.e., COVID-19 vaccination), and did not follow a formal development or validation process. However, these criteria might also be useful to assess whether questions from other research fields can and should be answered using the LSR approach, or assist in determining whether the use of an LSR is sensible and feasible for specific questions in health policy and practice.
Language	English
Publishing date	2024-03-21
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2412512-X
ISSN	2212-0289 ; 1865-9217
ISSN (online)	2212-0289
ISSN	1865-9217
DOI	10.1016/j.zefq.2024.01.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.110: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Changes in malaria epidemiology in Germany, 2001–2016

Sabine Vygen-Bonnet / Klaus Stark

Malaria Journal, Vol 17, Iss 1, Pp 1-

a time series analysis

2018 Volume 10

Abstract: Abstract Background German surveillance data showed a sharp rise of malaria cases in 2014 and 2015 due to the increased arrival of refugees from malaria endemic countries. A time series analysis of data from 2001 to 2016 was performed in order to ... ...

Abstract	Abstract Background German surveillance data showed a sharp rise of malaria cases in 2014 and 2015 due to the increased arrival of refugees from malaria endemic countries. A time series analysis of data from 2001 to 2016 was performed in order to describe the epidemiology of imported malaria in Germany in general and of the recent increase in particular. Results In total, 11,678 malaria cases were notified between 2001 and 2016 (range 526–1063 cases/year). Newly arriving refugees averaged 10 cases/year (1.5%) in 2001–13 and 292.5 cases/year (28.3%) in 2014–15. Plasmodium (P.) falciparum was the most frequently reported species (range 57.2–85.8%), followed by P. vivax (range during 2001–2013: 7.6–18.1%; during 2014–2015, mean 31.3%). In 2014–15, 22.3% of all P. vivax cases were refugees from Eritrea and 3.3% from other countries of the Horn of Africa; in 2015 and 2016, 19.5% were refugees from Afghanistan and Pakistan. Five P. knowlesi malaria infections were reportedly acquired in Thailand between 2012 and 2016. Total numbers of malaria notifications among native Germans and residents with migration background showed an increasing trend since 2007. Chemoprophylaxis use was reported for 24.3% (1695/6984) of cases and showed a declining trend. Native German cases took significantly more frequently chemoprophylaxis than cases with migration background (32.6% vs. 17.9%; p < 0.001). Discussion/conclusions The steep rise in vivax malaria notifications in 2014 and 2015 was mainly due to newly arriving refugees from Eritrea but also from other countries of the Horn of Africa and South Asia. Clinicians should include malaria in their differential diagnosis in case of a febrile illness in the respective population and consider vivax malaria even if arrival to Germany dates back several months. Over the past 10 years, malaria notifications among native Germans and residents with migration background showed an increasing trend. Use of chemoprophylaxis was insufficient in both groups and deteriorating. New strategies need ...
Keywords	Imported malaria ; P. vivax ; P. knowlesi ; Refugees ; Eritrea ; Germany ; Arctic medicine. Tropical medicine ; RC955-962 ; Infectious and parasitic diseases ; RC109-216
Subject code	360
Language	English
Publishing date	2018-01-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Changes in malaria epidemiology in Germany, 2001–2016

Vygen-Bonnet, Sabine / Stark, Klaus

a time series analysis

2018

Abstract	Background: German surveillance data showed a sharp rise of malaria cases in 2014 and 2015 due to the increased arrival of refugees from malaria endemic countries. A time series analysis of data from 2001 to 2016 was performed in order to describe the epidemiology of imported malaria in Germany in general and of the recent increase in particular. Results: In total, 11,678 malaria cases were notified between 2001 and 2016 (range 526–1063 cases/year). Newly arriving refugees averaged 10 cases/year (1.5%) in 2001–13 and 292.5 cases/year (28.3%) in 2014–15. Plasmodium (P.) falciparum was the most frequently reported species (range 57.2–85.8%), followed by P. vivax (range during 2001–2013: 7.6–18.1%; during 2014–2015, mean 31.3%). In 2014–15, 22.3% of all P. vivax cases were refugees from Eritrea and 3.3% from other countries of the Horn of Africa; in 2015 and 2016, 19.5% were refugees from Afghanistan and Pakistan. Five P. knowlesi malaria infections were reportedly acquired in Thailand between 2012 and 2016. Total numbers of malaria notifications among native Germans and residents with migration background showed an increasing trend since 2007. Chemoprophylaxis use was reported for 24.3% (1695/6984) of cases and showed a declining trend. Native German cases took significantly more frequently chemoprophylaxis than cases with migration background (32.6% vs. 17.9%; p < 0.001). Discussion/conclusions: The steep rise in vivax malaria notifications in 2014 and 2015 was mainly due to newly arriving refugees from Eritrea but also from other countries of the Horn of Africa and South Asia. Clinicians should include malaria in their differential diagnosis in case of a febrile illness in the respective population and consider vivax malaria even if arrival to Germany dates back several months. Over the past 10 years, malaria notifications among native Germans and residents with migration background showed an increasing trend. Use of chemoprophylaxis was insufficient in both groups and deteriorating. New strategies need to be ...
Keywords	Germany ; Refugees ; Imported malaria ; P. vivax ; P. knowlesi ; Eritrea ; Chemoprophylaxis ; 610 Medizin ; ddc:610
Subject code	360
Language	English
Publishing date	2018-01-15
Publisher	Robert Koch-Institut, Infektionsepidemiologie
Publishing country	de
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Changes in malaria epidemiology in Germany, 2001–2016

Vygen-Bonnet, Sabine / Stark, Klaus

a time series analysis

2018

Abstract	Background: German surveillance data showed a sharp rise of malaria cases in 2014 and 2015 due to the increased arrival of refugees from malaria endemic countries. A time series analysis of data from 2001 to 2016 was performed in order to describe the epidemiology of imported malaria in Germany in general and of the recent increase in particular. Results: In total, 11,678 malaria cases were notified between 2001 and 2016 (range 526–1063 cases/year). Newly arriving refugees averaged 10 cases/year (1.5%) in 2001–13 and 292.5 cases/year (28.3%) in 2014–15. Plasmodium (P.) falciparum was the most frequently reported species (range 57.2–85.8%), followed by P. vivax (range during 2001–2013: 7.6–18.1%; during 2014–2015, mean 31.3%). In 2014–15, 22.3% of all P. vivax cases were refugees from Eritrea and 3.3% from other countries of the Horn of Africa; in 2015 and 2016, 19.5% were refugees from Afghanistan and Pakistan. Five P. knowlesi malaria infections were reportedly acquired in Thailand between 2012 and 2016. Total numbers of malaria notifications among native Germans and residents with migration background showed an increasing trend since 2007. Chemoprophylaxis use was reported for 24.3% (1695/6984) of cases and showed a declining trend. Native German cases took significantly more frequently chemoprophylaxis than cases with migration background (32.6% vs. 17.9%; p < 0.001). Discussion/conclusions: The steep rise in vivax malaria notifications in 2014 and 2015 was mainly due to newly arriving refugees from Eritrea but also from other countries of the Horn of Africa and South Asia. Clinicians should include malaria in their differential diagnosis in case of a febrile illness in the respective population and consider vivax malaria even if arrival to Germany dates back several months. Over the past 10 years, malaria notifications among native Germans and residents with migration background showed an increasing trend. Use of chemoprophylaxis was insufficient in both groups and deteriorating. New strategies need to be found to increase compliance to chemoprophylaxis recommendations. The surveillance provides valuable data for epidemiological assessment of imported malaria in Germany.
Keywords	Medizin ; Germany ; Refugees ; Imported malaria ; P. vivax ; P. knowlesi ; Eritrea ; Chemoprophylaxis ; ddc:610
Subject code	360
Language	English
Publishing date	2018-01-15
Publisher	Infektionsepidemiologie
Publishing country	de
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Aktualisierung der Empfehlungen der STIKO zur Standardimpfung von Personen ≥ 60 Jahre sowie zur Indikationsimpfung von Risikogruppen gegen Pneumokokken und die dazugehörige wissenschaftliche Begründung

Schlaberg, Johanna / Vygen-Bonnet, Sabine / Falman, Annika / Wilhelm, Julia / Hummers, Eva / von Kries, Rüdiger / Ledig, Thomas / Bogdan, Christian

2023

Abstract: Erkrankungen durch S. pneumoniae gehören zu den häufigsten bakteriellen Atemwegsinfektionen weltweit. Auch in Deutschland sind Hospitalisierungen und Todesfälle aufgrund von Pneumokokken-Infektionen häufig. Personen ≥ 60 Jahre sowie Personen mit ... ...

Abstract	Erkrankungen durch S. pneumoniae gehören zu den häufigsten bakteriellen Atemwegsinfektionen weltweit. Auch in Deutschland sind Hospitalisierungen und Todesfälle aufgrund von Pneumokokken-Infektionen häufig. Personen ≥ 60 Jahre sowie Personen mit Vorerkrankungen haben ein besonderes Risiko für schwere invasive Pneumokokken-Erkrankungen. Aufgrund der Verfügbarkeit eines zusätzlichen 20-valenten Pneumokokken-Konjugatimpfstoffs (PCV20) aktualisiert die STIKO unter Berücksichtigung von Ergebnissen aus einem systematischen Review zur Sicherheit und Wirksamkeit des Impfstoffs und aus einer Modellierungsanalyse ihre Empfehlungen zur Standardimpfung für Personen ≥ 60 Jahre, zur Indikationsimpfung für Erwachsene mit bestimmten Risikofaktoren sowie zur beruflichen Indikationsimpfung. Peer Reviewed
Keywords	STIKO ; Impfempfehlung ; Pneumokokken ; Standardimpfung ; Indikationsimpfung ; 610 Medizin und Gesundheit ; ddc:610
Language	German
Publishing date	2023-09-28
Publisher	Robert Koch-Institut
Publishing country	de
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Aktualisierung der Empfehlungen der STIKO zur Standardimpfung von Personen ≥ 60 Jahre sowie zur Indikationsimpfung von Risikogruppen gegen Pneumokokken und die dazugehörige wissenschaftliche Begründung

Schlaberg, Johanna / Vygen-Bonnet, Sabine / Falman, Annika / Wilhelm, Julia / Hummers, Eva / von Kries, Rüdiger / Ledig, Thomas / Bogdan, Christian

2023

Abstract	Erkrankungen durch S. pneumoniae gehören zu den häufigsten bakteriellen Atemwegsinfektionen weltweit. Auch in Deutschland sind Hospitalisierungen und Todesfälle aufgrund von Pneumokokken-Infektionen häufig. Personen ≥ 60 Jahre sowie Personen mit Vorerkrankungen haben ein besonderes Risiko für schwere invasive Pneumokokken-Erkrankungen. Aufgrund der Verfügbarkeit eines zusätzlichen 20-valenten Pneumokokken-Konjugatimpfstoffs (PCV20) aktualisiert die STIKO unter Berücksichtigung von Ergebnissen aus einem systematischen Review zur Sicherheit und Wirksamkeit des Impfstoffs und aus einer Modellierungsanalyse ihre Empfehlungen zur Standardimpfung für Personen ≥ 60 Jahre, zur Indikationsimpfung für Erwachsene mit bestimmten Risikofaktoren sowie zur beruflichen Indikationsimpfung. Peer Reviewed
Keywords	STIKO ; Impfempfehlung ; Pneumokokken ; Standardimpfung ; Indikationsimpfung ; 610 Medizin und Gesundheit ; ddc:610
Language	German
Publishing date	2023-09-28
Publisher	Robert Koch-Institut
Publishing country	de
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis.

Piechotta, Vanessa / Siemens, Waldemar / Thielemann, Iris / Toews, Markus / Koch, Judith / Vygen-Bonnet, Sabine / Kothari, Kavita / Grummich, Kathrin / Braun, Cordula / Kapp, Philipp / Labonté, Valérie / Wichmann, Ole / Meerpohl, Joerg J / Harder, Thomas

The Lancet. Child & adolescent health

2023 Volume 7, Issue 6, Page(s) 379–391

Abstract: Background: To date, more than 761 million confirmed SARS-CoV-2 infections have been recorded globally, and more than half of all children are estimated to be seropositive. Despite high SARS-CoV-2 infection incidences, the rate of severe COVID-19 in ... ...

Abstract	Background: To date, more than 761 million confirmed SARS-CoV-2 infections have been recorded globally, and more than half of all children are estimated to be seropositive. Despite high SARS-CoV-2 infection incidences, the rate of severe COVID-19 in children is low. We aimed to assess the safety and efficacy or effectiveness of COVID-19 vaccines approved in the EU for children aged 5-11 years. Methods: In this systematic review and meta-analysis, we included studies of any design identified through searching the COVID-19 L·OVE (living overview of evidence) platform up to Jan 23, 2023. We included studies with participants aged 5-11 years, with any COVID-19 vaccine approved by the European Medicines Agency-ie, mRNA vaccines BNT162b2 (Pfizer-BioNTech), BNT162b2 Bivalent (against original strain and omicron [BA.4 or BA.5]), mRNA-1273 (Moderna), or mRNA-1273.214 (against original strain and omicron BA.1). Efficacy and effectiveness outcomes were SARS-CoV-2 infection (PCR-confirmed or antigen-test confirmed), symptomatic COVID-19, hospital admission due to COVID-19, COVID-19-related mortality, multisystem inflammatory syndrome in children (MIS-C), and long-term effects of COVID-19 (long COVID or post-COVID-19 condition as defined by study investigators or per WHO definition). Safety outcomes of interest were serious adverse events, adverse events of special interest (eg, myocarditis), solicited local and systemic events, and unsolicited adverse events. We assessed risk of bias and rated the certainty of evidence (CoE) using the Grading of Recommendations Assessment, Development and Evaluation approach. This study was prospectively registered with PROSPERO, CRD42022306822. Findings: Of 5272 screened records, we included 51 (1·0%) studies (n=17 [33%] in quantitative synthesis). Vaccine effectiveness after two doses against omicron infections was 41·6% (95% CI 28·1-52·6; eight non-randomised studies of interventions [NRSIs]; CoE low), 36·2% (21·5-48·2; six NRSIs; CoE low) against symptomatic COVID-19, 75·3% (68·0-81·0; six NRSIs; CoE moderate) against COVID-19-related hospitalisations, and 78% (48-90, one NRSI; CoE very low) against MIS-C. Vaccine effectiveness against COVID-19-related mortality was not estimable. Crude event rates for deaths in unvaccinated children were less than one case per 100 000 children, and no events were reported for vaccinated children (four NRSIs; CoE low). No study on vaccine effectiveness against long-term effects was identified. Vaccine effectiveness after three doses was 55% (50-60; one NRSI; CoE moderate) against omicron infections, and 61% (55-67; one NRSI; CoE moderate) against symptomatic COVID-19. No study reported vaccine efficacy or effectiveness against hospitalisation following a third dose. Safety data suggested no increased risk of serious adverse events (risk ratio [RR] 0·83 [95% CI 0·21-3·33]; two randomised controlled trials; CoE low), with approximately 0·23-1·2 events per 100 000 administered vaccines reported in real-life observations. Evidence on the risk of myocarditis was uncertain (RR 4·6 [0·1-156·1]; one NRSI; CoE low), with 0·13-1·04 observed events per 100 000 administered vaccines. The risk of solicited local reactions was 2·07 (1·80-2·39; two RCTs; CoE moderate) after one dose and 2·06 (1·70-2·49; two RCTs; CoE moderate) after two doses. The risk of solicited systemic reactions was 1·09 (1·04-1·16; two RCTs; CoE moderate) after one dose and 1·49 (1·34-1·65; two RCTs; CoE moderate) after two doses. The risk of unsolicited adverse events after two doses (RR 1·21 [1·07-1·38]; CoE moderate) was higher among mRNA-vaccinated compared with unvaccinated children. Interpretation: In children aged 5-11 years, mRNA vaccines are moderately effective against infections with the omicron variant, but probably protect well against COVID-19 hospitalisations. Vaccines were reactogenic but probably safe. Findings of this systematic review can serve as a basis for public health policy and individual decision making on COVID-19 vaccination in children aged 5-11 years. Funding: German Federal Joint Committee.
MeSH term(s)	Child ; Humans ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; BNT162 Vaccine ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; Myocarditis ; mRNA Vaccines ; Vaccines
Chemical Substances	mRNA-1273.214 COVID-19 vaccine ; COVID-19 Vaccines ; BNT162 Vaccine ; mRNA Vaccines ; Vaccines
Language	English
Publishing date	2023-04-18
Publishing country	England
Document type	Meta-Analysis ; Systematic Review ; Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2352-4650
ISSN (online)	2352-4650
DOI	10.1016/S2352-4642(23)00078-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Ständige Impfkommission (STIKO)

Koch, Judith / Vygen-Bonnet, Sabine / Wichmann, Ole

Die wichtigsten Änderungen im Überblick

2019

Abstract: ... Peer ... ...

Abstract	Peer Reviewed
Keywords	STIKO ; Ständige Impfkommission ; 610 Medizin und Gesundheit ; ddc:610
Language	German
Publishing date	2019-09-27
Publisher	Robert Koch-Institut
Publishing country	de
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED